The DOI matches its Crossref record.
TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME
Abstract
PURPOSE: Tumor progression and survival of patients with high grade Ta bladder tumors followed for 15 to 20 years were evaluated. MATERIALS AND METHODS: A total of 148 patients with Ta and 73 with T1 multiple, recurrent papillary bladder tumors were evaluated. In all patients complete transurethral resection was performed and 1 or more courses of bacillus Calmette-Guerin therapy were given. Minimum followup was 15 years. Of the Ta tumors 125 were high grade and 23 were low grade. The end points of the study were stage progression, defined as lamina propria invasion, muscle invasion or metastasis, and disease specific survival. RESULTS: The 15-year progression-free survival rate was 95% in the 23 patients with low grade Ta tumors and none died of disease. Progression-free survival and disease specific survival rates were 61% and 74%, respectively, in 125 patients with high grade Ta tumors compared to 44% and 62%, respectively, in 73 with T1 tumors. CONCLUSIONS: Patients with high grade Ta tumors have a lifelong risk of disease stage progression and death from bladder cancer similar to those with T1 tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60491-8 · Cited by 988
Economic aspects of bladder cancer: what are the benefits and costs?
Sievert, K. D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., & Stenzl, A. (2009) · World Journal of Urology · doi:10.1007/s00345-009-0395-z · Cited by 484
Böhle, A., & Bock, P. R. (2004) · Urology · doi:10.1016/j.urology.2003.11.049 · Cited by 465
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Metadata
- Authors
- HERR, H. W.
- Venue
- Journal of Urology
- Published
- 2000-01
- Volume
- 163
- Issue
- 1
- Pages
- 60-62
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2081006498
- Cited by
- 221
- References
- 0
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME. https://app.cochat.ai/papers/10.1016/s0022-5347(05)67972-4
- The paper
- HERR, H. W. (2000). TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67972-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
